Diabetologia

, Volume 48, Issue 6, pp 1229–1237 | Cite as

Cardiac dysfunction induced by high-fat diet is associated with altered myocardial insulin signalling in rats

  • D. M. Ouwens
  • C. Boer
  • M. Fodor
  • P. de Galan
  • R. J. Heine
  • J. A. Maassen
  • M. Diamant
Article

Abstract

Aims/hypothesis

Diabetic cardiomyopathy (DCM) is common in type 2 diabetes. In DCM, insulin resistance may alter cardiac substrate supply and utilisation leading to changes in myocardial metabolism and cardiac function. In rats, exposure to excessive alimentary fat, inducing a type 2 diabetic phenotype, may result in myocardial insulin resistance and cardiac functional changes resembling DCM.

Materials and methods

Rats received high-fat (HFD) or low-fat (LFD) diets for 7 weeks. Prior to killing, insulin or saline was injected i.p. Contractile function and insulin signalling were assessed in papillary muscles and ventricular lysates, respectively.

Results

Fasting and post-load blood glucose levels were increased in HFD- vs LFD-rats (all p<0.02). Mean heart weight, but not body weight, was increased in HFD-rats (p<0.01). HFD-hearts showed structural changes and triglyceride accumulation. HFD-muscles developed higher baseline and maximum forces, but showed impaired recovery from higher workloads. Insulin-associated modulation of Ca2+-induced force augmentation was abolished in HFD-muscles. HFD reduced insulin-stimulated IRS1-associated phosphatidylinositol 3′-kinase activity and phosphorylation of protein kinase B, glycogen synthase kinase-3β, endothelial nitric oxide synthase, and forkhead transcription factors by 40–60% (all p<0.05). Insulin-mediated phosphorylation of phospholamban, a critical regulator of myocardial contractility, was decreased in HFD-hearts (p<0.05).

Conclusions/interpretation

HFD induced a hypertrophy-like cardiac phenotype, characterised by a higher basal contractile force, an impaired recovery from increased workloads and decreased insulin-mediated protection against Ca2+ overload. Cardiac dysfunction was associated with myocardial insulin resistance and phospholamban hypophosphorylation. Our data suggest that myocardial insulin resistance, resulting from exposure to excessive alimentary fat, may contribute to the pathogenesis of diabetes-related heart disease.

Keywords

Diabetes mellitus Diabetic cardiomyopathy Diet Insulin Phospholamban 

Abbreviations

DCM

diabetic cardiomyopathy

eNOS

endothelial nitric oxide synthase

Fdev

developed force

Fmax

maximal force

Frec

recovered force

FOXO/FKHR

forkhead transcription factor

GSK3

glycogen synthase kinase 3

HFD

high-fat diet

LFD

low-fat diet

mTOR

mammalian target of rapamycin

PI3K

phosphatidylinositol 3′-kinase

PKB/Akt

protein kinase B

PLB

phospholamban

RyR

ryanodine receptor

SERCA2a

sarcoplasmic reticulum Ca2+ ATPase

Introduction

Type 2 diabetes is associated with a high incidence of coronary artery disease and congestive heart failure [1, 2]. Even in asymptomatic patients with uncomplicated type 2 diabetes, left ventricular hypertrophy and dysfunction are found [3, 4]. In the absence of coronary artery disease and hypertension, the myocardial abnormalities are ascribed to diabetic cardiomyopathy (DCM) [5]. Changes in myocardial energy metabolism, owing to altered cardiomyocyte substrate supply and utilisation, may underlie the development of DCM [6]. A key mechanism contributing to myocardial dysmetabolic changes may be impaired cardiac insulin signalling [6].

In insulin-resistant and type 2 diabetic subjects, high fluxes of NEFA and triglycerides exist because of unsuppressed lipolysis in adipose tissue and hepatic overproduction of triglyceride-rich particles. This excessive lipid exposure, in the presence of impaired glucose utilisation, results in accumulation of triglycerides in non-adipose tissues, including the myocardium. Inappropriate triglyceride deposition enlarges the intracellular pool of fatty acyl-CoA, thereby providing substrate for non-oxidative metabolic pathways leading to oxidative stress, cellular dysfunction and apoptosis [7]. In animal models of lipotoxicity, myocardial dysfunction was found, which was reversed by anti-steatotic treatment [8]. In vitro studies in cardiomyocytes from Zucker fatty rats suggest that impaired cardiac insulin signalling may underlie the observed abnormalities [9]. These findings are mainly derived from studies in genetic models of insulin resistance and type 2 diabetes, and therefore, it is unclear whether similar mechanisms operate in humans and animal models of alimentary fat-induced insulin resistance, which is believed to be fundamental in the development of human type 2 diabetes.

We investigated whether long-term exposure of normal rats to a high-fat diet (HFD), inducing a type 2 diabetic phenotype, results in myocardial dysfunction and whether these alterations are associated with abnormal myocardial insulin signalling.

Materials and methods

Animals

The investigation conformed to the Guide for the Care and Use of Laboratory Animals as published by the NIH (NIH Publ. No. 85-23, revised 1996) and the regulations of the Institutional Animal Care and Use Committee. Adult male Wistar (WU) rats (n=34; mean body weight 302±6 g; Harlan CBP, Horst, The Netherlands) were fed an HFD for 7 weeks. Animals that received an isocaloric low-fat diet (LFD) for 7 weeks served as controls. At week 6, rats fasted for 6–8 h received an oral glucose load (2 g/kg of body weight). Blood glucose was measured from tail bleeds with a HemoCue glucose analyser (Angelholm, Sweden) at 0, 15, 30, 60, 90 and 120 min after glucose ingestion. After 7 weeks, insulin stimulation was induced in fasted rats through i.p. injection of 10 U/kg body weight insulin (Actrapid 100 U/ml; Novo Nordisk, The Netherlands). Similar insulin levels were achieved in HFD- and LFD-rats. Animals were considered insulin-stimulated when plasma insulin levels exceeded 400 μU/ml. The effects of insulin were compared with those in animals that received a saline injection. Thirty minutes after saline or insulin injection, rats were killed by decapitation, and trunk blood was collected for glucose, insulin, leptin and NEFA determinations. Hearts were removed and transferred to ice-cold buffer containing (in mmol/l) 120 NaCl, 1.22 MgSO4, 1.99 NaH2PO4, 27 NaHCO3, 15 KCl, 1 CaCl2, 10 glucose, and 30 2,3-butanedione 2-monoxime, equilibrated with 95% O2 and 5% CO2. Hearts were perfused via the aorta with the chilled buffer and a papillary muscle with part of the septum and septal artery was dissected from the right ventricle [10]. The remaining ventricular tissue was either snap-frozen in dry-ice-chilled isopentane and stored at −80°C until analysis of insulin signalling, or fixed in Karnovky’s universal fixative (EMS15720) for electron microscopy.

Diets

Experimental diets were obtained from Hope Farms (Woerden, The Netherlands; HFD: cat#4148.02; LFD: cat#4148.01). The LFD consisted of 8 wt% total fat, 22 wt% protein and 60 wt% carbohydrate; the HFD contained 25 wt% fat, 32 wt% protein and 25 wt% carbohydrate, as well as more palmitate (91.12 g/kg) and oleate (100.24 g/kg) compared with the LFD (29.12 and 32.08 g/kg, respectively). In the case of the HFD, 50.4% of the ingested calories were derived from fat compared with 16.4% for the LFD.

In vitro contractile function

Papillary muscles were mounted in a superfusion bath and connected to a force transducer to assess contractile function [10]. The septal artery was cannulated and perfused at 60 cmH2O. The muscle was superfused and perfused by buffer containing (in mmol/l) 118 NaCl, 4.5 MgCl2, 4.5 KCl, 0.33 NaH2PO4, 25 NaHCO3, 1 CaCl2, 10 glucose and 0.01 adenosine, equilibrated with 95% O2 and 5% CO2 and kept at 27°C. Muscles were paced at 0.2 Hz and muscle dimensions were measured to enable normalisation of developed force (Fdev) and maximal force (Fmax) on muscle cross-sectional area. The length of the muscle was set at 95% of the maximal length as determined by a force–length relationship, followed by a stabilisation period of 60 min. Muscles were subjected to a potentiation protocol to determine Fmax. A force–frequency protocol was applied to increase muscle workload and subsequently recovery of force (Frec) was determined, which is expressed as a percentage of initial force. Finally, to study the effect of Ca2+ on Fdev, muscles were exposed to 2 mmol/l extracellular Ca2+.

Plasma determinations

Insulin was measured by RIA (INSIK-5; DiaSorin Biomedica, Saluggia, Italy), which shows 100% cross-reactivity with rat insulin. Plasma NEFA levels were determined using a colorimetric kit (WAKO NEFA-C; Wako Pure Chemical Industries, Osaka, Japan). Serum leptin concentrations were measured by RIA (LEP-R61; Mediagnost, Reutlingen, Germany).

Cardiac lipid analysis

Triglyceride content in ventricular lysates was determined as described previously [11].

Histology and electron microscopy

Frozen sections from liver, skeletal muscle and cardiac ventricular tissue were stained with oil-red-O and counterstained with Mayer’s haematoxylin. For electron microscopy, ultrathin sections of cardiac ventricular tissue were contrasted with uranyl acetate and Reynolds’ lead citrate.

Cardiac insulin signalling

To determine insulin signalling, ventricular tissue was homogenised using an ultraturrax mixer [9]. Lysates were centrifuged (15 min; 14,000 rpm; 4°C), and protein content was determined using a BCA kit (Pierce, Rockford, IL, USA).

The insulin receptor β-subunit, IRS1, and IRS2 were immunoprecipitated using polyclonal insulin receptor β-subunit antibody C19 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), IRS1 antibody K6, and IRS2 antibody K4, respectively [9]. Tyrosine phosphorylation of the immunoprecipitated proteins and IRS1/2-associated phosphatidylinositol 3′-kinase (PI3K) activity were determined as described [9]. Expression and phosphorylation of insulin signalling intermediates were analysed by Western blotting using anti-insulin receptor β-subunit (C19), anti-FOXO3/FKHRL1 (H144), anti-phosphotyrosine-horseradish peroxidase conjugate, anti-endothelial nitric oxide synthase (eNOS; C20), anti-ryanodine receptor (RyR; N19) (Santa Cruz Biotechnology), anti-phospholamban (PLB), anti-PLB-Ser16 (Upstate, Lake Placid, NY, USA), anti-FOXO1/FKHR, anti-glycogen synthase kinase 3β (GSK3β), and phospho-specific protein kinase B (PKB)/Akt-Thr308, PKB/Akt-Ser473, GSK3-Ser9/Ser21, eNOS-Ser1177, Forkhead/FOXO-Thr24, and mammalian target of rapamycin (mTOR)-Ser2448 antibodies (Cell Signaling Technology, Beverly, MA, USA). Polyclonal mTOR has been described [12], whereas PKB/Akt #5178, and sarcoplasmic reticulum Ca2+ ATPase (SERCA2a) antibodies were kindly provided by Dr B. Burgering (UMC Utrecht, The Netherlands) and Dr W. S. Simonides (Laboratory for Physiology, VUMC, Amsterdam, The Netherlands), respectively. Immunoblots were quantified by densitometric analysis of the films.

Statistical analysis

Data are expressed as means±SD or means±SE. Differences between groups were determined by an unpaired Student’s two-tailed t-test. A p value of p<0.05 was considered statistically significant.

Results

HFD induces a non-obese phenotype with impaired glucose tolerance

Mean baseline body weights in LFD- and HFD-rats (302±4.6 and 301±3.7 g, respectively), and overall mean body weight gain during the course of the diet intervention (mean 49±4 days; 132±31 and 131±30 g, respectively) were similar. Fasting (p<0.001) and post-load blood glucose levels (p<0.02) were significantly higher in HFD- than in LFD-rats (Table 1, Fig. 1a). A significant short-term rise in post-load plasma insulin levels was observed in HFD-rats only (p<0.05; Fig. 1b). At killing, no differences in plasma insulin, leptin and NEFA levels were found between the two groups (Table 1). Insulin injection suppressed plasma NEFA levels by 74.4% (p<0.001) in LFD-rats and by 26.7% (p=0.111) in HFD-animals. Only the HFD induced skeletal muscle and liver steatosis (Fig. 1c–f).
Table 1

Characteristics of rats after 7 weeks on a high- or low-fat diet

 

Low-fat diet

High-fat diet

Body weight at killing (g)

458±27 (n=16)

461±29 (n=18)

Fasting blood glucose (mmol/l)

6.0±0.55 (n=16)

6.84±0.51 (n=18)a

Fasting plasma insulin (pmol/l)

398±97 (n=8)

315±83 (n=5)

Plasma leptin (mg/l)

15.1±4.3 (n=16)

13.4±4.2 (n=17)

Fasting plasma NEFA (mmol/l)

0.39±0.11 (n=6)

0.30±0.07 (n=6)

Heart weight (g)

1.96±0.13 (n=15)

2.16±0.20 (n=15)b

(Heart weight:body weight ratio)×1,000

4.29±0.24 (n=15)

4.67±0.34 (n=14)b

Cardiac triglycerides (μg/mg protein)

181±50 (n=3)

330±114 (n=5)c

Values are means±SD

ap<0.001 vs low-fat

bp<0.01 vs low-fat

cp<0.02 vs low-fat

Fig. 1

Blood glucose levels following an oral glucose load in rats fed an HFD (black circles; n=16) and an LFD (white circles; n=13) (a). Data are expressed as means±SE, *p<0.02, diet effect. Baseline corrected plasma insulin levels following an oral glucose load in HFD- (black circles; n=5) and LFD-rats (white circles; n=5) (b). Data are expressed as means±SE, *p<0.05. Histological examination revealed lipid accumulation in the liver and skeletal muscle of HFD-rats (d and f), but not in LFD-rats (c and e). Scale bar=100 μm

HFD-feeding results in cardiac structural and functional abnormalities

Mean heart weight and heart-to-body-weight ratio of HFD-rats were increased as compared with LFD-animals (both p<0.01; Table 1). Electron microscopy revealed marked ultrastructural abnormalities in cardiomyocytes from HFD-rats, in particular degenerative changes of mitochondria, including matrix dilution, cristolysis and mitochondria-associated lamellar bodies (Fig. 2). Biochemical analysis showed a twofold rise in cardiac triglyceride content in HFD- vs LFD-rats (p<0.02; Table 1).
Fig. 2

Transmission electronmicrographs of cardiac sections of LFD- (a) and HFD-rats (bd). Normal mitochondria (m) with clearly visible cristae are present in LFD-cardiomyocytes, whereas degenerated mitochondria (arrow) are present in HFD-cells. Higher magnification revealed lamellar structures associated with mitochondrial membranes (star symbol)

Increases in basal Fdev and Fmax of 1.7- (p<0.01) and 1.6-fold (p<0.05), respectively were observed in papillary muscles obtained from saline-injected HFD-rats, as compared with those from LFD-rats (Fig. 3a,b). Similarly, Fdev showed a 1.4-fold increase (p<0.05) in muscles from insulin-injected HFD- vs LFD-animals, but, when compared with the saline-injected groups, the stimulatory effect of insulin on Fdev only reached significance in LFD-animals (Fig. 3a). Fmax was not affected by insulin (Fig. 3b).
Fig. 3

Basal (a) and maximum (b) force development and recovery (c) after increased workload in papillary muscles from LFD- and HFD-fed rats (white bars=saline; black bars=insulin; n=6 in each condition). Data are expressed as means±SE, *p<0.05, diet effect; #p<0.05, insulin effect

Following an enhanced workload, Frec equalled 69.1 and 65.8% of baseline Fdev in saline- and insulin-injected LFD- animals, respectively (Fig. 3c), and 36.6 and 47.3% in the corresponding muscles from HFD-rats (both p<0.05), indicating an impaired recovery of HFD muscles. Increasing the buffer Ca2+ concentration to 2 mmol/l induced a rise in Fdev in both LFD- and HFD-muscles from saline-injected rats (both p<0.05; Fig. 4a). The Ca2+-induced Fdev augmentation was blunted in muscles from insulin-injected LFD-rats (p<0.05), but this insulin-mediated protective effect against Ca2+-overload was abolished in muscles from HFD-rats (Fig. 4a). These findings were not explained by differences in expression levels of sarcoplasmic reticulum Ca2+-cycling proteins RyR and SERCA2a (Fig. 4b). However, a 43% decrease in Ser16-PLB phosphorylation/PLB expression ratio was observed in hearts from insulin-injected HFD-rats (p<0.05 vs LFD; Fig. 4b,c), suggesting an increased inhibitory action of PLB on SERCA2a activity.
Fig. 4

Prior insulin injection attenuated the Ca2+-induced increase in developed force (Fdev) in LFD-, but not in HFD-papillary muscles (a). Data are expressed as means±SE changes in Fdev after exposure to 2 mmol/l Ca2+, relative to Fdev at 1 mmol/l Ca2+. Immunoblots (b) showing expression and/or phosphorylation of RyR, SERCA2a, PLB and PLB-Ser16. Quantification of PLB, PLB-Ser16 and the ratio PLB-Ser16:PLB (c). *p<0.05, diet effect; #p<0.05, insulin effect

HFD reduces activation of multiple myocardial insulin signalling pathways

Phosphorylation of PKB/Akt and its substrates

Insulin markedly increased both Thr308- and Ser473-PKB/Akt phosphorylation in LFD-hearts. PKB/Akt phosphorylation in HFD-hearts was reduced by 64 (Thr308; p<0.02) and 45% (Ser473; p<0.005) relative to LFD, respectively (Fig. 5a,b). Protein expression of PKB/Akt was similar in LFD- and HFD-animals (Fig. 5a). Phosphorylation of the PKB/Akt-substrates eNOS-Ser1177, GSK3β-Ser9 and FOXO1/3-Thr24 was increased in hearts from insulin-injected LFD-rats, but not in HFD-hearts (Fig. 5c). The blunted response to insulin of cardiac mTOR-Ser2448 phosphorylation in HFD- vs LFD-rats did not reach significance (Fig. 5c). Protein expression of the PKB/Akt-substrates did not differ among the experimental groups (Fig. 5d).
Fig. 5

Immunoblots (a) and the quantification (b) of PKB/Akt-Thr308 and Ser473 phosphorylation (white bars=saline; black bars=insulin; n=8 each condition). Immunoblots for phosphorylation (c) and expression (d) of eNOS, FOXO1/3, GSK3β and mTOR. Data are expressed as means±SE, *p<0.05, diet effect; #p<0.05, insulin effect

Tyrosine phosphorylation of IRS1/IRS2 and associated PI3K activity

Insulin stimulation resulted in a 2.4-fold increase in IRS1 tyrosine phosphorylation in LFD-hearts (Fig. 6a,b), whereas the levels of tyrosine phosphorylated IRS1 were diminished by 57% in HFD-hearts (p<0.001; Fig. 6a,b). Furthermore, insulin induced a 4.7- vs 2.8-fold increase in IRS1-associated PI3K activity in LFD- vs HFD-hearts (p<0.02; Fig. 6a,b). No difference was found in protein expression levels of IRS1 (Fig. 6c). The insulin-induced increase in tyrosine phosphorylation of IRS2 and IRS2-associated PI3K activity failed to reach significance under the experimental conditions used in this study (data not shown).
Fig. 6

Analysis (a) and quantification (b) of IRS1 immunoprecipitates for tyrosine phosphorylation (pTyr) and associated PI3K activity (white bars=saline; black bars=insulin). Immunoblot of IRS1 expression from saline-injected rats on an LFD and HFD (c). Data are expressed as means±SE, *p<0.05, diet effect; #p<0.05, insulin effect

Tyrosine phosphorylation of the insulin receptor β-subunit

Insulin induced tyrosine phosphorylation of the insulin receptor β-subunit in both groups (Fig. 7a). However, the response to insulin in HFD- vs LFD-rats was reduced by 50% (p<0.05; Fig. 7b). Expression of the insulin receptor protein was similar in both groups (Fig. 7c).
Fig. 7

Anti-phosphotyrosine (pTyr) immunoblot (a) and quantification (b) of insulin receptor β-subunit immunoprecipitates (white bars=saline; black bars=insulin). Immunoblot of IRβ-subunit expression from saline-injected rats on an LFD and HFD (c). Data are means±SE. *p<0.05, diet effect

Discussion

Rats fed an HFD developed a type 2 diabetic phenotype, characterised by glucose intolerance and hepatic, skeletal muscle and cardiac steatosis, but with a body weight gain similar to that of LFD controls. HFD-feeding resulted in mild cardiac hypertrophy with higher baseline contractile forces but a markedly diminished recovery after higher workloads. Also, a blunted force-augmentation response to high Ca2+ was observed in insulin-injected HFD-rat papillary muscles, and cardiac ultrastructural abnormalities were found in the HFD-heart only. Furthermore, hearts from insulin-injected HFD-rats showed impaired insulin signalling and PLB hypophosphorylation.

So far, most studies investigating cardiac lipotoxicity have been performed in genetically manipulated rodents, particularly in leptin-deficient or -resistant animals [8, 13]. Therefore, it was unclear whether cardiac lipid accumulation could be induced by mere dietary HFD intake in normal animals. Normal rats fed a 60% HFD for 6 weeks had only a slight elevation of cardiac triglyceride content [7], whereas 10-week-old leptin-deficient ob/ob mice fed standard chow showed a three-fold increase in heart triglyceride content, relative to controls [13]. We found a two-fold increase in cardiac triglyceride content after 7 weeks of HFD-feeding in normal rats, indicating that chronic exposure to a high dietary fat content can indeed induce cardiac lipid accumulation and the associated abnormalities [14, 15].

The observed cardiac hypertrophy in the HFD-rats may be regarded as a first step in the sequence of adaptive responses of the heart to stress caused by a large number of physiological and pathological conditions [16]. Indeed, papillary muscles from the HFD-hearts showed higher basal and maximum forces, but a decreased recovery after higher workload. The underlying mechanism linking HFD-feeding to development of mild cardiac hypertrophy is unclear. On the one hand, hyperinsulinaemia has been implicated in the regulation of cardiac growth [17]. Alternatively, a contribution of triglyceride accumulation and sustained protein kinase C activation through triglyceride metabolites to the hypertrophic changes in HFD-hearts cannot be excluded [18]. Finally, although diet-related blood pressure elevations, contributing to the cardiac hypertrophy, cannot be entirely ruled out, the existence of relevant hypertension in our rats is less likely since no concentric hypertrophy was found (data not shown). Others have shown that blood pressure changes in rats given a 74% fat-containing diet for 17 weeks were unremarkable [19].

Myocardial metabolic changes, i.e. increased NEFA oxidation at the expense of glucose uptake and metabolism, influence cardiac energy status and as such may have contributed to the observed functional alterations in HFD-muscles [20]. Although cardiac metabolism was not assessed, the observed signalling defects as well as the impaired capacity to recover from higher workloads are indicative of an impaired glucose metabolism in HFD-hearts. An increased NEFA supply will not only diminish the rate of glucose metabolism, but will also further increase oxygen consumption both by uncoupling oxidative phosphorylation [21] and by inducing cycling of NEFA in and out of the triglyceride pool, a futile, energy-consuming cycle [22]. Ischaemia is not likely to account for the observed changes since the muscle preparation was continuously perfused with oxygenated buffer [10]. In addition, high levels of NEFA may influence energy consumption related to excitation–contraction coupling as well as other processes related to cellular Ca2+ handling [23, 24]. Therefore, the energetic disadvantage of the predominant use of NEFA as a myocardial energy substrate may result in the reduced ability to recover from a workload challenge.

Associations between myocardial metabolic abnormalities and dysfunction have been reported by some authors [24, 25, 26, 27], but not by others [28, 29]. These discrepancies may be the result of differences in animal models and the methods used to assess cardiac function, including substrate availability and the presence or absence of myocardial ischaemia. Insulin may be an important link between myocardial metabolism and function [17, 30, 31]; however, data on insulin-mediated effects and molecular aspects of insulin signalling are largely lacking from the aforementioned studies. Insulin improves cardiac energy efficiency by shifting substrate utilisation towards glucose, and in theory these changes may favourably affect myocardial function, in particular in the hypertrophic heart and under ischaemic conditions. These beneficial effects of insulin were shown both in animals [20], and in humans [32].

HFD-papillary muscles displayed functional insulin resistance, as reflected by the absence of positive inotropy and impaired protection against Ca2+ overload. An altered myocardial contractile response to insulin was previously described in models of diabetes and cardiac hypertrophy [33, 34, 35, 36, 37]. Alterations in cardiomyocyte Ca2+ handling in streptozotocin-induced diabetic hearts have been linked to decreased expression and activation of SERCA2a, amongst others through interaction with IRS1/2 [38, 39]. We found no effect of insulin on SERCA2a–IRS1/2 association (data not shown), and, in line with other studies in animal models of insulin resistance/type 2 diabetes, no diet-induced alterations in SERCA2a and RyR expression [40, 41]. However, the observed decrease in Ser16-PLB phosphorylation levels in insulin-injected HFD-hearts may have contributed to the impaired insulin-mediated protection against Ca2+ overload, as a reduction in Ser16-PLB phosphorylation increases the inhibitory action of PLB on SERCA2a activity [42].

At the molecular level, insulin resistance in HFD-hearts was reflected by impaired activation of the insulin receptor and IRS1/PI3K/PKB/Akt-mediated signalling. Although studies regarding insulin receptor activation in the skeletal muscle of type 2 diabetic subjects have yielded conflicting results [43], defects in insulin receptor activation were reported in skeletal muscle from HFD-rats [44] as well as in hearts from leptin-deficient rodents [45, 46]. Various studies have linked NEFA metabolites, like ceramides and diacylglycerol, to activation of protein kinase C, Jun N-terminal kinase, and inhibitor of nuclear factor-κB kinase, which in their turn can abrogate insulin signalling through serine phosphorylation of the insulin receptor and its substrates [14]. We found triglyceride accumulation in skeletal and cardiac muscle from HFD-rats in the presence of unaltered circulating NEFA levels, suggesting that an increased supply of NEFA originating from intramyocellular triglyceride stores, rather than elevated circulating NEFA levels, could be responsible for the observed cardiac insulin resistance. Furthermore, activation of protein phosphatases contributing to impaired insulin signalling in HFD-hearts cannot be ruled out, since preliminary data indicate a slight elevation of protein phosphatase 2A expression in HFD-hearts (data not shown), which has been implicated in the dephosphorylation of, amongst others, PKB/Akt and PLB [47, 48].

The decreased activation of PKB/Akt-mediated signalling in HFD-hearts may result not only in decreased GLUT4-mediated glucose uptake and glycogen synthesis [14], but also in adverse effects on cardiac function. Reduced phosphorylation of eNOS may impair nitric oxide generation and vasodilatation, thereby adversely affecting cardiac function [49]. Finally, here we report for the first time the insulin-mediated phosphorylation of the forkhead transcription factors FOXO1/3 in the heart. Phosphorylation of the forkhead transcription factors FOXO1/3 by PKB/Akt results in their nuclear exclusion and concurrent loss of their gene regulatory function [50]. Although in vitro studies implicate FOXO proteins in cell cycle control, cell survival and apoptosis, their function in the heart clearly depends on future target gene identification.

Taken together, an HFD induced a type 2 diabetic phenotype in rats, cardiac dysfunction and both functional and molecular myocardial insulin resistance. Insulin exerts many different effects that collectively may, directly or indirectly, have a beneficial impact on the heart. However, it still remains to be demonstrated whether insulin can effect these additional actions independently of its metabolic effects. Interventions aimed at ameliorating cardiac insulin signalling may constitute a major therapeutic contribution in the battle against diabetes-related heart disease.

Notes

Acknowledgements

The authors wish to thank Dr H. Niessen (Department of Pathology, VU University Medical Centre, Amsterdam, The Netherlands) for helpful discussions, and Gerard van der Zon (Department of Molecular Cell Biology, LUMC, The Netherlands) and Maarten Tushuizen (Department of Endocrinology, VU University Medical Centre, Amsterdam, The Netherlands) for technical assistance.

References

  1. 1.
    Kannel WB, Hjortland M, Castelli WP (1974) Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 34:29–34CrossRefPubMedGoogle Scholar
  2. 2.
    Stamler J, Vaccaro O, Neaton JD, Wentworth D (1993) Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16:434–444PubMedGoogle Scholar
  3. 3.
    Vanninen E, Mustonen J, Vainio P, Lansimies E, Uusitupa M (1992) Left ventricular function and dimensions in newly diagnosed non-insulin-dependent diabetes mellitus. Am J Cardiol 70:371–378CrossRefPubMedGoogle Scholar
  4. 4.
    Diamant M, Lamb HJ, Groeneveld Y et al (2003) Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol 42:328–335CrossRefPubMedGoogle Scholar
  5. 5.
    Bell DS (1995) Diabetic cardiomyopathy. A unique entity or a complication of coronary artery disease? Diabetes Care 18:708–714PubMedGoogle Scholar
  6. 6.
    Taegtmeyer H, McNulty P, Young ME (2002) Adaptation and maladaptation of the heart in diabetes: part I. General concepts. Circulation 105:1727–1733CrossRefPubMedGoogle Scholar
  7. 7.
    Unger RH (2002) Lipotoxic diseases. Annu Rev Med 53:319–336CrossRefPubMedGoogle Scholar
  8. 8.
    Zhou YT, Grayburn P, Karim A et al (2000) Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A 97:1784–1789CrossRefPubMedGoogle Scholar
  9. 9.
    Kessler A, Uphues I, Ouwens DM, Till M, Eckel J (2001) Diversification of cardiac insulin signaling involves the p85 alpha/beta subunits of phosphatidylinositol 3-kinase. Am J Physiol Endocrinol Metab 280:E65–E74PubMedGoogle Scholar
  10. 10.
    Lamberts RR, Van Rijen MH, Sipkema P, Fransen P, Sys SU, Westerhof N (2002) Coronary perfusion and muscle lengthening increase cardiac contraction: different stretch-triggered mechanisms. Am J Physiol Heart Circ Physiol 283:H1515–H1522PubMedGoogle Scholar
  11. 11.
    Bligh EG, Dyer WJ (1959) A rapid method of total lipid extraction and purification. Can J Med Sci 37:911–917Google Scholar
  12. 12.
    Withers DJ, Ouwens DM, Nave BT et al (1997) Expression, enzyme activity, and subcellular localization of mammalian target of rapamycin in insulin-responsive cells. Biochem Biophys Res Commun 241:704–709CrossRefPubMedGoogle Scholar
  13. 13.
    Christoffersen C, Bollano E, Lindegaard MLS et al (2003) Cardiac lipid accumulation associated with diasystolic dysfunction in obese mice. Endocrinology 144:3483–3490CrossRefPubMedGoogle Scholar
  14. 14.
    Perseghin G, Petersen K, Shulman GI (2003) Cellular mechanism of insulin resistance: potential links with inflammation. Int J Obes Relat Metab Disord 27(Suppl 3):S6–S11CrossRefPubMedGoogle Scholar
  15. 15.
    Schaffer JE (2003) Lipotoxicity: when tissues overeat. Curr Opin Lipidol 14:281–287CrossRefPubMedGoogle Scholar
  16. 16.
    Frey N, Katus HA, Olson EN, Hill JA (2004) Hypertrophy of the heart: a new therapeutic target? Circulation 109:1580–1589CrossRefPubMedGoogle Scholar
  17. 17.
    Belke DD, Betuing S, Tuttle MJ et al (2002) Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. J Clin Invest 109:629–639CrossRefPubMedGoogle Scholar
  18. 18.
    Murphy S, Frishman WH (2005) Protein kinase C in cardiac disease and as a potential therapeutic target. Cardiol Rev 13:3–12PubMedGoogle Scholar
  19. 19.
    Fitzgerald SM, Henegar JR, Brands MW, Henegar LK, Hall JE (2001) Cardiovascular and renal responses to a high-fat diet in Osborne–Mendel rats. Am J Physiol Regul Integr Comp Physiol 281:R547–R552PubMedGoogle Scholar
  20. 20.
    Korvald C, Elvenes OP, Myrmel T (2000) Myocardial substrate metabolism influences left ventricular energetics in vivo. Am J Physiol Heart Circ Physiol 278:H1345–H1351PubMedGoogle Scholar
  21. 21.
    Borst P, Loos JA, Christ EJ, Slater EC (1962) Uncoupling activity of long-chain fatty acids. Biochim Biophys Acta 62:509–518CrossRefPubMedGoogle Scholar
  22. 22.
    Myrmel T, Forsdahl K, Larsen TS (1992) Triacylglycerol metabolism in hypoxic, glucose-deprived rat cardiomyocytes. J Mol Cell Cardiol 24:855–868CrossRefPubMedGoogle Scholar
  23. 23.
    Philipson KD, Ward R (1985) Effects of fatty acids on Na+–Ca2+ exchange and Ca2+ permeability of cardiac sarcolemmal vesicles. J Biol Chem 260:9666–9671PubMedGoogle Scholar
  24. 24.
    Huang JM, Xian H, Bacaner M (1992) Long-chain fatty acids activate calcium channels in ventricular myocytes. Proc Natl Acad Sci U S A 89:6452–6456PubMedGoogle Scholar
  25. 25.
    Chiu HC, Kovacs A, Ford DA et al (2001) A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest 107:813–822PubMedGoogle Scholar
  26. 26.
    Finck BN, Lehman JJ, Leone TC et al (2002) The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 109:121–130CrossRefPubMedGoogle Scholar
  27. 27.
    Young ME, Guthrie PH, Razeghi P et al (2002) Impaired long-chain fatty acid oxidation and contractile dysfunction in the obese Zucker rat heart. Diabetes 51:2587–2595PubMedGoogle Scholar
  28. 28.
    Abel ED, Kaulbach HC, Tian R et al (1999) Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart. J Clin Invest 104:1703–1714PubMedGoogle Scholar
  29. 29.
    Atkinson LL, Kozak R, Kelly SE, Onay BA, Russell JC, Lopaschuk GD (2003) Potential mechanisms and consequences of cardiac triacylglycerol accumulation in insulin-resistant rats. Am J Physiol Endocrinol Metab 284:E923–E930PubMedGoogle Scholar
  30. 30.
    Hu P, Zhang D, Swenson L, Chakrabarti G, Abel ED, Litwin SE (2003) Minimally invasive aortic banding in mice: effects of altered cardiomyocyte insulin signaling during pressure overload. Am J Physiol Heart Circ Physiol 285:H1261–H1269PubMedGoogle Scholar
  31. 31.
    Dutta K, Podolin DA, Davidson MB, Davidoff AJ (2001) Cardiomyocyte dysfunction in sucrose-fed rats is associated with insulin resistance. Diabetes 50:1186–1192PubMedGoogle Scholar
  32. 32.
    Fath-Ordoubadi F, Beatt KJ (1997) Glucose–insulin–potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation 96:1152–1156PubMedGoogle Scholar
  33. 33.
    Ren J, Walsh MF, Hamaty M, Sowers JR, Brown RA (1999) Augmentation of the inotropic response to insulin in diabetic rat hearts. Life Sci 65:369–380CrossRefPubMedGoogle Scholar
  34. 34.
    Ren J, Sowers JR, Walsh MF, Brown RA (2000) Reduced contractile response to insulin and IGF-I in ventricular myocytes from genetically obese Zucker rats. Am J Physiol Heart Circ Physiol 279:H1708–H1714PubMedGoogle Scholar
  35. 35.
    Allard MF, Wambolt RB, Longnus SL et al (2000) Hypertrophied rat hearts are less responsive to the metabolic and functional effects of insulin. Am J Physiol Endocrinol Metab 279:E487–E493PubMedGoogle Scholar
  36. 36.
    Doenst T, Goodwin GW, Cedars AM, Wang M, Stepkowski S, Taegtmeyer H (2001) Load-induced changes in vivo alter substrate fluxes and insulin responsiveness of rat heart in vitro. Metabolism 50:1083–1090CrossRefPubMedGoogle Scholar
  37. 37.
    Sasso FC, Carbonara O, Cozzolino D et al (2000) Effects of insulin–glucose infusion on left ventricular function at rest and during dynamic exercise in healthy subjects and noninsulin dependent diabetic patients: a radionuclide ventriculographic study. J Am Coll Cardiol 36:219–226CrossRefPubMedGoogle Scholar
  38. 38.
    Netticadan T, Temsah RM, Kent A, Elimban V, Dhalla NS (2001) Depressed levels of Ca2+-cycling proteins may underlie sarcoplasmic reticulum dysfunction in the diabetic heart. Diabetes 50:2133–2138PubMedGoogle Scholar
  39. 39.
    Algenstaedt P, Antonetti DA, Yaffe MB, Kahn CR (1997) Insulin receptor substrate proteins create a link between the tyrosine phosphorylation cascade and the Ca2+-ATPases in muscle and heart. J Biol Chem 272:23696–23702CrossRefPubMedGoogle Scholar
  40. 40.
    Dutta K, Carmody MW, Cala SE, Davidoff AJ (2002) Depressed PKA activity contributes to impaired SERCA function and is linked to the pathogenesis of glucose-induced cardiomyopathy. J Mol Cell Cardiol 34:985–996CrossRefPubMedGoogle Scholar
  41. 41.
    Belke DD, Swanson EA, Dillmann WH (2004) Decreased sarcoplasmic reticulum activity and contractility in diabetic db/db mouse heart. Diabetes 53:3201–3208PubMedGoogle Scholar
  42. 42.
    MacLennan DH, Kranias EG (2003) Phospholamban: a crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol 4:566–577CrossRefPubMedGoogle Scholar
  43. 43.
    Zierath JR, Krook A, Wallberg-Henriksson H (2000) Insulin action and insulin resistance in human skeletal muscle. Diabetologia 43:821–835CrossRefPubMedGoogle Scholar
  44. 44.
    Youngren JF, Paik J, Barnard RJ (2001) Impaired insulin-receptor autophosphorylation is an early defect in fat-fed, insulin-resistant rats. J Appl Physiol 91:2240–2247PubMedGoogle Scholar
  45. 45.
    Mazumder PK, O’Neill BT, Roberts MW et al (2004) Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes 53:2366–2374PubMedGoogle Scholar
  46. 46.
    Carvalheira JB, Calegari VC, Zecchin HG et al (2003) The cross-talk between angiotensin and insulin differentially affects phosphatidylinositol 3-kinase- and mitogen-activated protein kinase-mediated signaling in rat heart: implications for insulin resistance. Endocrinology 144:5604–5614CrossRefPubMedGoogle Scholar
  47. 47.
    Cazzolli R, Carpenter L, Biden TJ, Schmitz-Peiffer C (2001) A role for protein phosphatase 2A-like activity, but not atypical protein kinase Czeta, in the inhibition of protein kinase B/Akt and glycogen synthesis by palmitate. Diabetes 50:2210–2218PubMedGoogle Scholar
  48. 48.
    Gergs U, Boknik P, Buchwalow I et al (2004) Overexpression of the catalytic subunit of protein phosphatase 2A impairs cardiac function. J Biol Chem 279:40827–40834CrossRefPubMedGoogle Scholar
  49. 49.
    Gao F, Gao E, Yue TL et al (2002) Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: the roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation 105:1497–1502CrossRefPubMedGoogle Scholar
  50. 50.
    Accili D, Arden KC (2004) FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 117:421–426CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • D. M. Ouwens
    • 1
  • C. Boer
    • 2
  • M. Fodor
    • 3
    • 5
  • P. de Galan
    • 1
  • R. J. Heine
    • 4
  • J. A. Maassen
    • 1
    • 4
  • M. Diamant
    • 4
  1. 1.Department of Molecular Cell BiologyLeiden University Medical CentreLeidenThe Netherlands
  2. 2.Laboratory for PhysiologyVU University Medical CentreAmsterdamThe Netherlands
  3. 3.Department of PaediatricsVU University Medical CentreAmsterdamThe Netherlands
  4. 4.Department of Endocrinology/Diabetes CentreVU University Medical CentreAmsterdamThe Netherlands
  5. 5.Department of Anatomy and EmbryologyLeiden University Medical CentreLeidenThe Netherlands

Personalised recommendations